Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07276009

Probiotics in Functional Dyspepsia

The goal of this clinical trial is to learn whether a multi-strain probiotic can reduce digestive symptoms and improve quality of life in adults with functional dyspepsia. The main questions it aims to answer are:

* Does the probiotic reduce symptoms such as fullness after meals, bloating, stomach discomfort, and early satiation? * Does the probiotic improve emotional well-being, including stress, anxiety, and mood? Researchers will compare the probiotic to a placebo (a look-alike capsule with no active ingredients) to see if the probiotic truly helps adults with functional dyspepsia.

Participants will:

* Take one capsule of the probiotic or placebo once daily before meals for 60 days * Complete questionnaires about their digestive symptoms at the start, 1 month, and 2 months * Complete surveys on stress, anxiety, depression, and quality of life at the start and 2 months * Attend scheduled study visits for checkups and assessments

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65 years
  • Diagnosis of Functional Dyspepsia based on Rome IV criteria, with symptoms present for at least 3 months, and symptom onset at least 6 months before diagnosis, including:
  • Postprandial fullness
  • Early satiation
  • Epigastric pain or burning
  • (with no evidence of structural disease explaining symptoms)
  • Moderate to severe symptom severity at baseline, as defined by a validated scale (e.g., NDI or global symptom score)
  • Normal upper GI endoscopy within the last 12 months (or at screening), excluding structural disease (e.g., peptic ulcer, malignancy)
  • Negative for H. pylori (either previously treated successfully or tested negative within study screening)
  • Ability and willingness to provide informed consent and comply with study procedures
  • Stable medication use, if any, for at least 4 weeks before screening (e.g., PPIs, antidepressants, laxatives)

Exclusion criteria

  • Evidence of structural GI disease (e.g., peptic ulcer, gastric cancer, celiac disease) on recent or screening endoscopy
  • History of gastrointestinal surgery affecting stomach or small intestine (except appendectomy or cholecystectomy)
  • Positive test for H. pylori during screening (or untreated known infection)
  • Current or recent use (within 4 weeks) of antibiotics, pre-, pro- or postbiotics, unless part of study protocol
  • Use of medications affecting GI motility (e.g., prokinetics, opioids, anticholinergics) within 2-4 weeks before enrollment
  • Overlap with other functional GI disorders (except IBS) if they are the dominant complaint, unless your protocol allows overlap
  • Clinically significant psychiatric illness (e.g., major depression, schizophrenia) that may interfere with symptom reporting or adherence
  • Severe systemic or metabolic disease (e.g., uncontrolled diabetes, renal or hepatic failure)
  • Pregnancy or lactation, or intention to become pregnant during the study period
  • Participation in another clinical trial within the past 3 months
  • Known allergy or intolerance to study product components

Treatment and study plan

Lactobacillus

Other

5 billion CFU of lactobacilus ans streptococci once daily for 60 days

Maltodextrin (Placebo)

Other

Placebo capsules will be given one a day for 60 days

Primary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale

    Time frame: 30 and 60 days

Study contacts

Contact information is provided by the study sponsor or research team.

Małgorzata Tyx-Dąbkowska

CONTACT

[email protected]

+48604494452

Sergiy Gerasymov, MD, PhD

CONTACT

[email protected]

+380679375951

Sponsors and collaborators

Lead sponsor

Nordic Biotic Sp. z o.o.

Industry

Registry information

Official study title

The Effect of Multi-strain Probiotic Formulation on Gastrointestinal Symptoms, Quality of Life and Mental Health in Patients With Functional Dyspepsia: a Randomized Dietary Trial

Acronym: ProPepsis

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 10, 2025
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.